When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Anti-VEGF - Wikipedia

   en.wikipedia.org/wiki/Anti-VEGF

   By May 2012, anti-VEGF treatment with Avastin has been accepted by Medicare, is quite reasonably priced, and effective. Lucentis has a similar but smaller molecular structure to Avastin, and is FDA-approved (2006) for treating MacD, yet remains more costly, as is the more recent (approved in 2011) aflibercept (Eylea). Tests on these treatments ...

3. Aflibercept - Wikipedia

   en.wikipedia.org/wiki/Aflibercept

   Aflibercept, sold under the brand names Eylea and Zaltrap among others, is a medication used to treat wet macular degeneration and metastatic colorectal cancer. [ 14 ] [ 15 ] It was developed by Regeneron Pharmaceuticals .

4. US FDA approves higher dose of Regeneron's eye disease drug Eylea

   www.aol.com/news/us-fda-approves-higher-dose...

   The drug, Eylea HD, is priced at $2,625 per single-use vial in the U.S. and is used to treat patients with wet age-related macular degeneration (AMD), diabetic macular edema (DME) and diabetic ...

5. Intravitreal administration - Wikipedia

   en.wikipedia.org/wiki/Intravitreal_administration

   There are three widely used Anti-VEGF drugs to treat these conditions: ranibizumab (Lucentis®; Genentech), bevacizumab (Avastin®; Genentech), and aflibercept (Eylea®; Regeneron Pharmaceuticals). Bevacizumab has not been FDA approved to treat wet AMD however in the US it is the first line anti-VEGF therapy for over half of ophthalmologists ...

6. Drugmakers to raise US prices on over 250 medicines starting ...

   www.aol.com/news/drugmakers-raise-us-prices-over...

   Drugmakers plan to raise U.S. prices on at least 250 branded medications including Pfizer COVID-19 treatment Paxlovid, Bristol Myers Squibb's cancer cell therapies and vaccines from France's ...

7. Should You Buy the Dip on This Top Growth Stock? - AOL

   www.aol.com/buy-dip-top-growth-stock-103000464.html

   In the second quarter, combined U.S. sales of Eylea and Eylea HD came in at $1.53 billion, an increase of 2% compared to the year-ago period; Eylea's HD revenue accounted for $304 million of that ...

8. Annual pharmaceutical drug sales - Wikipedia

   en.wikipedia.org/wiki/Annual_pharmaceutical_drug...

   Avastin Metastatic colorectal cancer, non-small cell lung cancer (NSCLC), renal cell carcinoma, HER2-negative breast cancer Genentech: $2,686 $2,296 $1,746 $1,132 $554.6 erlotinib: Tarceva Advanced (metastatic) non-small cell lung cancer (NSCLC) Genentech: $457 $417 $402 $274.9 $13.3 brimonidine: Alphagan Open-angle glaucoma or ocular ...

9. US FDA approves two biosimilars for blockbuster eye drug Eylea

   www.aol.com/news/us-fda-approves-two-biosimilars...

   Regeneron has filed lawsuits against companies such as Amgen and Biocon, which are seeking to bring Eylea biosimilars to the U.S. market.Regeneron recorded U.S. sales of $5.72 billion from its ...